These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 37999876)
1. Comprehensive Analysis for Predicting Prognoses and Immune Responses of m6A-Related lncRNAs in Women with Lung Adenocarcinoma. Wu S; Tu Q; Yuan H; Wu Z; Yang Y; Chen C; Huang C Biochem Genet; 2024 Aug; 62(4):2702-2720. PubMed ID: 37999876 [TBL] [Abstract][Full Text] [Related]
2. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment. Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861 [TBL] [Abstract][Full Text] [Related]
3. Development of m6A/m5C/m1A regulated lncRNA signature for prognostic prediction, personalized immune intervention and drug selection in LUAD. Ma C; Gu Z; Yang Y J Cell Mol Med; 2024 Apr; 28(8):e18282. PubMed ID: 38647237 [TBL] [Abstract][Full Text] [Related]
4. Disulfidptosis-related lncRNAs signature predicting prognosis and immunotherapy effect in lung adenocarcinoma. Hong S; Zhang Y; Wang D; Wang H; Zhang H; Jiang J; Chen L Aging (Albany NY); 2024 Jun; 16(11):9972-9989. PubMed ID: 38862217 [TBL] [Abstract][Full Text] [Related]
5. Consensus clustering and novel risk score model construction based on m6A methylation regulators to evaluate the prognosis and tumor immune microenvironment of early-stage lung adenocarcinoma. He M; Zhi Y; Li C; Zhao C; Yang G; Lv J; You H; Huang H; Cao X Aging (Albany NY); 2024 Jul; 16(14):11318-11338. PubMed ID: 39028290 [TBL] [Abstract][Full Text] [Related]
6. Identification of an immune-related six-long noncoding RNA signature as a novel prognosis biomarker for adenocarcinoma of lung. Miao H; Chen D; Li R; Hu J; Chen Y; Xu C; Wen Z Biosci Rep; 2021 Jan; 41(1):. PubMed ID: 33324975 [TBL] [Abstract][Full Text] [Related]
7. Development and validation of the potential biomarkers based on m6A-related lncRNAs for the predictions of overall survival in the lung adenocarcinoma and differential analysis with cuproptosis. Gao C; Kong N; Zhang F; Zhou L; Xu M; Wu L BMC Bioinformatics; 2022 Aug; 23(1):327. PubMed ID: 35941550 [TBL] [Abstract][Full Text] [Related]
8. Comprehensive analysis of m6A modification patterns and m6A-related lncRNAs as potential biomarkers in lung adenocarcinoma. Wang S; Gu X; Xu D; Liu B; Qin K; Yuan X Environ Toxicol; 2024 Apr; 39(4):2285-2303. PubMed ID: 38148718 [TBL] [Abstract][Full Text] [Related]
9. Comprehensive Analysis of Tumor Immune Microenvironment and Prognosis of m6A-Related IncRNAs in Lung Adenocarcinoma. Shen Y; Hou N; Han F; Chen B; Shi J; Sun X Crit Rev Eukaryot Gene Expr; 2022; 32(5):77-91. PubMed ID: 35993946 [TBL] [Abstract][Full Text] [Related]
10. Analysis of N6-methyladenosine-related lncRNAs in the tumor immune microenvironment and their prognostic role in pancreatic cancer. Liu Y; Wang T; Fang Z; Kong J; Liu J J Cancer Res Clin Oncol; 2022 Jul; 148(7):1613-1626. PubMed ID: 35314871 [TBL] [Abstract][Full Text] [Related]
11. A Novel m6A-Related LncRNA Signature for Predicting Prognosis, Chemotherapy and Immunotherapy Response in Patients with Lung Adenocarcinoma. Shen Y; Wang S; Wu Y Cells; 2022 Aug; 11(15):. PubMed ID: 35954243 [TBL] [Abstract][Full Text] [Related]
12. Comprehensive Analysis of N6-Methyladenosine-Related lncRNA Signature for Predicting Prognosis and Immune Cell Infiltration in Patients with Colorectal Cancer. Zhao Z; Yang YB; Li XY; Li XG; Chu XD; Lin ZB; Zhang YR; Guo YG; Ding H; Pan YL; Wang L; Pan JH Dis Markers; 2021; 2021():8686307. PubMed ID: 34745388 [TBL] [Abstract][Full Text] [Related]
13. Construction of lncRNA-m6A gene-mRNA regulatory network to identify m6A-related lncRNAs associated with the progression of lung adenocarcinoma. Zhang J; Bai S; Yan Y; Kang H; Li G; Feng Z; Ma W; Wang X; Ren J BMC Pulm Med; 2023 Aug; 23(1):284. PubMed ID: 37537521 [TBL] [Abstract][Full Text] [Related]
14. Relationships of N6-Methyladenosine-Related Long Non-Coding RNAs With Tumor Immune Microenvironment and Clinical Prognosis in Lung Adenocarcinoma. Zhao J; Lin X; Zhuang J; He F Front Genet; 2021; 12():714697. PubMed ID: 34777460 [No Abstract] [Full Text] [Related]
15. N6-Methyladenosine-Related lncRNA Signature Predicts the Overall Survival of Colorectal Cancer Patients. Song W; Ren J; Yuan W; Xiang R; Ge Y; Fu T Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573357 [TBL] [Abstract][Full Text] [Related]
16. Comprehensive analysis of tumor immune microenvironment and prognosis of m6A-related lncRNAs in gastric cancer. Wang Y; Zhu GQ; Tian D; Zhou CW; Li N; Feng Y; Zeng MS BMC Cancer; 2022 Mar; 22(1):316. PubMed ID: 35331183 [TBL] [Abstract][Full Text] [Related]
17. An exosomes-related lncRNA prognostic model correlates with the immune microenvironment and therapy response in lung adenocarcinoma. Chu D; Chen L; Li W; Zhang H Clin Exp Med; 2024 May; 24(1):104. PubMed ID: 38761234 [TBL] [Abstract][Full Text] [Related]
18. N-6 methylation-related lncRNA is potential signature in lung adenocarcinoma and influences tumor microenvironment. Zheng J; Zhao Z; Wan J; Guo M; Wang Y; Yang Z; Li Z; Ming L; Qin Z J Clin Lab Anal; 2021 Nov; 35(11):e23951. PubMed ID: 34558724 [TBL] [Abstract][Full Text] [Related]
19. NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis. Liu XS; Zhou LM; Yuan LL; Gao Y; Kui XY; Liu XY; Pei ZJ Front Immunol; 2021; 12():724741. PubMed ID: 34335635 [TBL] [Abstract][Full Text] [Related]
20. N6-methyladenosine-related lncRNAs identified as potential biomarkers for predicting the overall survival of Asian gastric cancer patients. Xu S; Chen W; Wang Y; Zhang Y; Xia R; Shen J; Gong X; Liang Y; Xu J; Tang H; Zhao T; Zhang Y; Chen T; Wang C BMC Cancer; 2022 Jul; 22(1):721. PubMed ID: 35778697 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]